Analysts predict that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will post earnings per share of ($0.23) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Ironwood Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.28). Ironwood Pharmaceuticals reported earnings of ($0.18) per share during the same quarter last year, which would suggest a negative year over year growth rate of 27.8%. The firm is scheduled to issue its next earnings results before the market opens on Thursday, November 2nd.
On average, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($1.16) per share for the current fiscal year, with EPS estimates ranging from ($1.28) to ($1.08). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.53) per share, with EPS estimates ranging from ($0.75) to ($0.35). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). The company had revenue of $65.10 million during the quarter, compared to analysts’ expectations of $70.00 million. Ironwood Pharmaceuticals had a negative return on equity of 333.83% and a negative net margin of 52.97%. The firm’s revenue was up 19.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.16) EPS.
A number of brokerages have recently weighed in on IRWD. J P Morgan Chase & Co reiterated a “neutral” rating and set a $19.00 target price (down previously from $20.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, July 21st. Mizuho increased their target price on Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, July 4th. BidaskClub lowered Ironwood Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Cowen and Company reiterated an “outperform” rating and set a $20.00 target price on shares of Ironwood Pharmaceuticals in a research note on Sunday, July 23rd. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $18.29.
WARNING: “Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Earnings of -$0.23 Per Share” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2017/10/30/analysts-expect-ironwood-pharmaceuticals-inc-irwd-will-announce-earnings-of-0-23-per-share.html.
Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 15.11 on Monday. Ironwood Pharmaceuticals has a 1-year low of $12.48 and a 1-year high of $19.94. The stock’s market capitalization is $2.26 billion. The stock’s 50 day moving average price is $15.69 and its 200 day moving average price is $16.73.
Institutional investors have recently bought and sold shares of the business. Oppenheimer Asset Management Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 592.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 17,878 shares of the biotechnology company’s stock valued at $338,000 after purchasing an additional 15,295 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 3.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 80,693 shares of the biotechnology company’s stock valued at $1,377,000 after purchasing an additional 2,913 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Ironwood Pharmaceuticals by 281.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 101,676 shares of the biotechnology company’s stock valued at $1,920,000 after purchasing an additional 75,055 shares in the last quarter. State of Wisconsin Investment Board boosted its holdings in shares of Ironwood Pharmaceuticals by 148.4% in the 2nd quarter. State of Wisconsin Investment Board now owns 621,000 shares of the biotechnology company’s stock valued at $11,724,000 after purchasing an additional 371,000 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in shares of Ironwood Pharmaceuticals by 20.3% in the 2nd quarter. First Trust Advisors LP now owns 94,732 shares of the biotechnology company’s stock valued at $1,789,000 after purchasing an additional 16,018 shares in the last quarter. Hedge funds and other institutional investors own 97.88% of the company’s stock.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Ironwood Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ironwood Pharmaceuticals Inc. and related companies.